Tpg Gp A LLC Takes Position in CeriBell (NASDAQ:CBLL)

Tpg Gp A LLC acquired a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,967,422 shares of the company's stock, valued at approximately $102,677,000. CeriBell comprises approximately 1.7% of Tpg Gp A LLC's investment portfolio, making the stock its 12th largest position. Tpg Gp A LLC owned approximately 11.08% of CeriBell as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Rhumbline Advisers purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $320,000. Corebridge Financial Inc. purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $158,000. PNC Financial Services Group Inc. purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $47,000. Massachusetts Financial Services Co. MA purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $10,750,000. Finally, Vanguard Group Inc. bought a new position in CeriBell in the fourth quarter worth approximately $18,015,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the transaction, the chief executive officer now owns 727,151 shares in the company, valued at $10,987,251.61. This trade represents a 2.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 24,700 shares of company stock worth $372,434 over the last 90 days. 20.10% of the stock is owned by insiders.

CeriBell Stock Up 2.2%

CBLL opened at $17.97 on Monday. The company has a fifty day moving average of $17.50 and a 200 day moving average of $22.35. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. Sell-side analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CBLL shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell (NASDAQ:CBLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.